Biogen Inc. (BIIB) NASDAQ

196.45

+0.49(+0.25%)

Updated at June 04 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Christopher A. Viehbacher	President, Chief Executive Officer & Director	5.28M	1961
Rachid Izzar	Executive Vice President and Head of Global Product Strategy & Commercialization	1.27M	1975
Ginger Gregory	Executive Vice President & Chief Human Resources Officer	1.59M	1968
Robin C. Kramer	Executive Vice President & Chief Financial Officer	1.63M	1966
Priya Singhal	Executive Vice President & Head of Development	2.01M	1968
Nicole Murphy	Executive Vice President and Head of Pharmaceutical Operations & Technology	2.01M	1973
Susan H. Alexander	Executive Vice President & Chief Legal Officer	2.25M	1957
Sean Godbout	VP, Chief Accounting Officer & Global Corporate Controller	0	1974
Tim Power	Head of Investor Relations	0	N/A
Fraser Hall	President & Head of Intercontinental Region	0	N/A
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	0	1960
Adam Keeney	Executive Vice President & Head of Corporate Development	0	1977
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	0	N/A
Alisha A. Alaimo	President & Head of North America	0	N/A
Guy Hadari	Chief Information Officer	0	N/A

Name

Title

Pay

Year Born

Christopher A. Viehbacher

President, Chief Executive Officer & Director

5.28M

1961

Rachid Izzar

Executive Vice President and Head of Global Product Strategy & Commercialization

1.27M

1975

Ginger Gregory

Executive Vice President & Chief Human Resources Officer

1.59M

1968

Robin C. Kramer

Executive Vice President & Chief Financial Officer

1.63M

1966

Priya Singhal

Executive Vice President & Head of Development

2.01M

1968

Nicole Murphy

Executive Vice President and Head of Pharmaceutical Operations & Technology

2.01M

1973

Susan H. Alexander

Executive Vice President & Chief Legal Officer

2.25M

1957

Sean Godbout

VP, Chief Accounting Officer & Global Corporate Controller

1974

Tim Power

Head of Investor Relations

N/A

Fraser Hall

President & Head of Intercontinental Region

N/A

Anabella Villalobos

Head of Biotherapeutics & Medicinal Sciences

1960

Adam Keeney

Executive Vice President & Head of Corporate Development

1977

Natacha Gassenbach

Chief Communication Officer & Head of Corporate Affairs

N/A

Alisha A. Alaimo

President & Head of North America

N/A

Guy Hadari

Chief Information Officer

N/A

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.